FrancophonIA/ELRC3.0 huggingface dataset:
English: If the patient misses an instillation, the patient should be told to continue the treatment with the next instillation.
Estonian: Patsientidele tuleb öelda, et kui üks manustamiskord jääb vahele, tuleb ravi jätkata järgmisel manustamiskorral.
English: Cysteamine reduces corneal cystine crystal accumulation acting as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides.
Estonian: Tsüsteamiin vähendab tsüstiinikristallide kogunemist sarvkestale, toimides tsüstiini kõrvaldavalt, muundades tsüstiini tsüsteiiniks ning tsüsteiini-tsüsteamiini segadisulfiidideks.
English: Do not drive or use machines until your vision is clear.
Estonian: Kuni nägemise selginemiseni ärge juhtige autot ega käsitsege masinaid.
English: How to store Cystadrops 6.
Estonian: Kuidas Cystadropsi säilitada 6.
English: One mL of eye drops solution contains 3.8 mg of cysteamine.
Estonian: Üks ml silmatilkade lahust sisaldab 3,8 mg tsüsteamiini.
English: The effect on pregnancy of untreated cystinosis is also unknown.
Estonian: Samuti on teadmata ravimata tsüstinoosi toime rasedusele.
English: • abnormal sensation in eye, a feeling of something in the eye
Estonian: • ebatavaline tunne silmas, võõrkeha tunne silmas
English: After first opening: keep the dropper bottle tightly closed in the outer carton in order to protect from light.
Estonian: Pärast esmast avamist: hoida tilgapudel tihedalt suletuna välispakendis, valguse eest kaitstult.
English: • Wash your hands carefully in order to avoid contamination by bacteria of the content in the vial.
Estonian: • Viaali sisu bakteritegasaastumise vältimiseks peske hoolikalt käed.
English: Move firmly the dropper bottle up and down to facilitate the filing of the dropper.
Estonian: Liigutage tilgapudelit kindlalt üles-alla, et tilguti korralikult täituks.
English: The following adverse reactions were reported during clinical trials and the French NPU programme with Cystadrops.
Estonian: Kliinilistes uuringutes ning Prantsusmaal Cystadropsiga läbi viidud NPU programmis täheldati järgmisi kõrvaltoimeid.
English: Very common : instillation site discomfort (mainly sticky eyes and sticky eyelashes)
Estonian: Väga sage: ebamugavustunne manustamiskohas (peamiselt silmade kleepumine ja silmalaugude kleepumine) Sage: valu manustamiskohas
English: How to use Cystadrops
Estonian: Kuidas Cystadropsi kasutada
English: Benzalkonium chloride (see leaflet for further information), disodium edetate, carmellose sodium, citric acid monohydrate, sodium hydroxide, hydrochloric acid, water for injections.
Estonian: Bensalkooniumkloriid (lisateavet vt infolehest), dinaatriumedetaat, naatriumkarmelloos, sidrunhappe monohüdraat, naatriumhüdroksiid, soolhape, süstevesi.
English: Pregnancy and breast-feeding Even if the level of Cystadrops in the blood is negligible, precautions should be taken.
Estonian: Isegi kui Cystadropsi sisaldus veres on väga madal, tuleb rakendada ettevaatusabinõusid.
English: • visual impairement
Estonian: • hägustunud nägemine
English: • Place the dropper bottle into the carton box.
Estonian: • Asetage tilgapudel pappkarpi.
English: Before the first admnistration, in order to facilitate the administration, the patient should be told to bring back Cystadrops at room temperature.
Estonian: Patsienti tuleb enne esimest manustamist teavitada, et manustamise hõlbustamiseks tuleb Cystadropsil lasta soojeneda toatemperatuurile.
English: Dose adaptation was performed following ocular examination.
Estonian: Annust kohandati vastavalt silmauuringutele.
English: Very common : eye pain, vision blurred, eye irritation, ocular hyperaemia, eye pruritus, lacrimation increased, deposit eye
Estonian: Väga sage: valu silmas, nägemise hägustumine, silma ärritus, okulaarne hüpereemia, kihelus silmas, suurenenud pisaravool, ladestus silmas
English: What Cystadrops is
Estonian: Mida Cystadrops sisaldab
English: Common : abnormal sensation in eye, dry eye, foreign body sensation in eye, eyelid oedema, eyelid irritation, visual impairment, hordeolum
Estonian: Sage: ebatavaline tunne silmas, kuiv silm, võõrkeha tunne silmas, silmalau turse, silmalau ärritus, nägemise halvenemine, odraiva
English: The recommended total daily ocular dose of cysteamine is no more than approximately 0.4% of the highest recommended dose of oral cysteamine in any age group.
Estonian: Tsüsteamiini okulaarne soovitatav ööpäevane koguannus ei ole suurem kui umbes 0,4% iga vanusegrupi jaoks soovitatavast suurimast suukaudsest tsüsteamiini annusest.
English: Discard 7 days after first opening.
Estonian: Visata ära 7 päeva pärast esmast avamist.
English: Administer eye ointments last.
Estonian: Silmasalvid manustageviimasena .
English: Do not use the drops with your lenses in. After using the drops wait 15 minutes before putting your lenses back in.
Estonian: Pärast tilkade kasutamist oodake 15 minutit, enne kui läätsed tagasi silma panete.
English: Overdose is unlikely to occur with ocular administration.
Estonian: Okulaarse manustamise korral on üleannustamine ebatõenäoline.
English: If you are worried, talk to your doctor or pharmacist.
Estonian: Kui need teevad teile muret, pidage nõu oma arsti või apteekriga.
English: Each mL contains mercaptamine hydrochloride equivalent to 3.8 mg mercaptamine (cysteamine).
Estonian: Üks ml sisaldab merkaptamiinvesinikkloriidi, mis on ekvivalentne 3,8 mg merkaptamiiniga (tsüsteamiiniga).
English: How to store Cystadrops
Estonian: Kuidas Cystadropsi säilitada
English: Cystadrops 3.8 mg/mL eye drops solution
Estonian: Cystadrops 3,8 mg/ml silmatilgad, lahus
English: Benzalkonium chloride Disodium edetate
Estonian: Bensalkooniumkloriid Dinaatriumedetaat
English: The following side effects were reported:
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
English: Cystadrops 3.8 mg/mL eye drops solution cysteamine (mercaptamine)
Estonian: Cystadrops 3,8 mg/ml silmatilgad, lahus tsüsteamiin (merkaptamiin)
English: Cysteamine excretion in human's milk is unknown.
Estonian: Tsüsteamiini eritumine inimese rinnapiima ei ole teada.
English: A trend towards a lower IVCM total score in Cystadrops arm was observed at day 30.
Estonian: 30. päeval täheldati Cystadropsi raviharus trendi madalama IVCM-i koondskoori suunas.
English: Cystadrops 3.8 mg/mL eye drops solution cysteamine
Estonian: Cystadrops 3,8 mg/ml silmatilgad, lahus tsüsteamiin
English: • Keep the dropper bottle tightly closed in the outer carton in order to protect from light.
Estonian: • Hoida tilgapudelit tihedalt suletuna välispakendis, valguse eest kaitstult.
English: • The recommended interval between each application is 4 hours (for example, you can have your eye drops at 8.00 am, 12.00 am, 4.00 pm and 8.00 pm).
Estonian: 8.00, 12.00, 16.00 ja 20.00).
English: • Write down the date you opened the vial in the space on the carton.
Estonian: • Kirjutage viaali avamise kuupäev pappkarbil selleks ette nähtud kohta.
English: Recordati Rare Diseases Immeuble "Le Wilson" 70, avenue du Général de Gaulle FR-92800 Puteaux France
Estonian: Recordati Rare Diseases Immeuble “Le Wilson” 70, avenue du Général de Gaulle F - 92800 Puteaux Prantsusmaa
English: After first opening, the patient should be told to keep the dropper bottle at room temperature.
Estonian: Patsienti tuleb teavitada, et pärast esmaavamist tuleb tilgapudelit hoida toatemperatuuril.
English: Keep the dropper bottle tightly closed in the outer carton in order to protect from light.
Estonian: Hoida tilgapudelit tihedalt suletuna välispakendis, valguse eest kaitstult.
English: Benzalkonium chloride is known to discolour soft contact lenses.
Estonian: Bensalkooniumkloriid põhjustab teadaolevalt pehmete kontaktläätsede värvikahjustusi.
English: Do not use a double dose to make up for a forgotten dose.
Estonian: Ärge kasutage kahekordset annust, kui annus jäi eelmisel korral kasutamata.
English: Eye drops solution.
Estonian: Silmatilgad, lahus.
English: • Keep the vial in the outer carton in order to protect from light.
Estonian: • Hoida viaali välispakendis, valguse eest kaitstult.
English: Viscous, clear solution.
Estonian: Viskoosne läbipaistev lahus.
English: What Cystadrops is and what it is used for 2.
Estonian: 1. Mis ravim on Cystadrops ja milleks seda kasutatakse 2. Mida on vaja teada enne Cystadropsi kasutamist 3.
English: Recordati
Estonian: KÕLBLIKKUSAEG
English: Each mL contains 3.8 mg of cysteamine (mercaptamine), as hydrochloride.
Estonian: Üks ml sisaldab 3,8 mg tsüsteamiin (merkaptamiin) vesinikkloriid.
English: • Bring the dropper bottle tip close to the eye. Use the mirror if it helps.
Estonian: • Tõstke tilgapudeli otsik silma lähedale.
English: • eye pain
Estonian: • silmalau paistetus
English: CARTON BOX
Estonian: Naatriumkarmelloos
English: Four main studies were performed in about 800 patients after an operation.
Estonian: Tehti neli põhiuuringut, milles osales ligikaudu 800 operatsioonijärgset patsienti.
English: It is a well-known substance, which has been used to control pain for many years.
Estonian: See on hästi tuntud aine, mida on kasutatud valuvaigistina palju aastaid.
English: It must then be removed by a doctor or nurse.
Estonian: Seejärel peab arst või õde seadme eemaldama.
English: Medicinal product no longer authorise©EMEA 2008
Estonian: Ravimil on müügiluba lõppenu©EMEA 2008
English: The European Commission granted a marketing authorisation valid throughout the European Union for IONSYS to Janssen-Cilag International NV on 24 January 2006.
Estonian: Euroopa Komisjon väljastas IONSYSi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Janssen-Cilag International NV 24. jaanuaril 2006.
English: IONSYS can be used up to six times in one hour, but for no more than 80 doses within a 24-hour period.
Estonian: IONSYSi saab kasutada kuni 6 korda tunnis, kuid üksnes kuni 80 annuse manustamiseks ööpäeva jooksul.
English: The Committee recommended that IONSYS be given marketing authorisation.
Estonian: Komitee soovitas anda IONSYSile müügiloa.
English: The system will stop working 24 hours after the first dose or after 80 doses have been delivered.
Estonian: Seade lakkab töötamast 24 tundi pärast esimest annust või pärast 80. annuse manustamist.
English: The company that makes IONSYS will monitor the key safety risks associated with IONSYS such as overdose, abuse, addiction or misuse, and will provide an educational plan for patients, doctors and healthcare providers, aimed at minimising the risk and supporting the safe and effective use of the medicine.
Estonian: IONSYSi tootja jälgib peamisi IONSYSiga kaasnevaid ohutusriske nagu üleannustamine, väärtarvitamine, sõltuvus või vale kasutusviis ning ta esitab patsientidele, arstidele ja tervishoiuteenuse pakkujatele teabekava, mille eesmärgiks on riskide minimeerimine ning ravimi ohutu ja efektiivse kasutamise toetamine.
English: Which measures are being taken to ensure the safe use of IONSYS?
Estonian: Milliseid meetmed võetakse, et tagada Ionsysi kasutamise ohutus?
English: IONSYS must only be used in hospital, and it must not be used in patients who have respiratory problems (such as breathing difficulties), or heart, liver or kidney problems.
Estonian: IONSYSi tohib kasutada ainult haiglatingimustes ja seda ei tohi kasutada patsientidel, kellel on hingamiselundite probleeme (nt hingamisraskused) või südame-, maksa- või neeruprobleeme.
English: These studies measured the number of patients who stopped treatment because they were not getting enough pain relief.
Estonian: Uuringutes leiti nende patsientide arv, kes lõpetasid ravi, sest see ei vaigistanud valu piisavalt.
English: IONSYS is given to the patient after an operation.
Estonian: IONSYS antakse patsiendile operatsiooni järel.
English: The results of the study comparing IONSYS with morphine were insufficient to determine whether the two medicines were of similar effectiveness in relieving pain or not.
Estonian: IONSYSi morfiiniga võrrelnud uuringu tulemused olid ebapiisavad otsustamaks, kas nende kahe ravimi efektiivsus valu vaigistamisel on sarnane või mitte.
English: Other information about IONSYS:
Estonian: Muu teave IONSYSi kohta
English: A doctor or a nurse applies the transdermal system to the patient's skin on the chest or upper arm.
Estonian: Arst või õde paigaldab nahakaudse manustamise seadme patsiendi nahale (rindkerele või käsivarrele).
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that IONSYS offers potential benefits compared to systems where the pain relief is given via a vein: it is non-invasive, needle-free and pre-programmed, and it can be activated by the patient.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et IONSYSil on võimalikke eeliseid valuvaigistite veenikaudsete manustussüsteemide ees: see on mitteinvasiivne, ilma nõelata, eelprogrammeeritud ja seda juhib patsient.
English: When in pain, the patient uses a button on the IONSYS system to start the delivery of a dose of fentanyl (40 micrograms).
Estonian: Valu korral vajutab patsient IONSYSi nuppu, et käivitada fentanüüli annuse (40 mikrogrammi) manustamine.
English: The fentanyl is contained inside a reservoir.
Estonian: Fentanüül sisaldub seadme sees väikeses mahutis.
English: In the studies where IONSYS was compared to placebo, the proportion of patients who stopped treatment because their pain was not controlled was lower in patients treated with IONSYS than those treated with placebo.
Estonian: Uuringutes, kus IONSYSi võrreldi platseeboga, oli vaigistamatu valu tõttu ravi lõpetanud patsientide arv IONSYSiga ravitud patsientide seas väiksem kui platseeboga ravitud patsientide seas.
English: The most common side effects with IONSYS (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, headache and erythema (redness of the skin) at the site of application.
Estonian: IONSYSi kõige sagedamad kõrvalnähud (mida on esinenud rohkem kui ühel patsiendil kümnest) on iiveldus, oksendamine, peavalu ja manustuskoha nahapunetus.
English: The fourth study compared IONSYS to morphine given by injection into a vein, and looked at the number of patients who judged their pain relief as ‘good' or ‘excellent'.
Estonian: Neljandas uuringus võrreldi IONSYSi toimet veeni süstitava morfiiniga ja leiti nende patsientide arv, kelle arvates oli valuvaigistav toime hea või suurepärane.
English: In three of them, IONSYS was compared with placebo (a transdermal system identical to IONSYS, but from which the medicine could not be released).
Estonian: Neist uuringuist kolmes võrreldi IONSYSi platseeboga (IONSYSiga sarnane nahakaudne seade, mis ei vabastanud ravimit).
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IONSYS EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE (EPAR)
English: What is the risk associated with IONSYS?
Estonian: Millised on IONSYSiga kaasnevad riskid?
English: These results show that IONSYS has a benefit in controlling pain after an operation.
Estonian: Tulemused näitasid, et IONSYS on operatsioonijärgse valu vaigistamisel kasulik.
English: Once in the bloodstream, fentanyl acts on receptors in the brain and spinal cord to prevent pain.
Estonian: Vereringes olev fentanüül mõjub pea- ja seljaaju retseptoritele, vaigistades valu.
English: What is IONSYS?
Estonian: Mis on IONSYS?
English: For the full list of all side effects reported with IONSYS, see the Package Leaflet.
Estonian: IONSYSi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: It is given using a system that is operated by the patient.
Estonian: See on patsiendi poolt juhitav valuvaigistamise seade.
English: Why has IONSYS been approved?
Estonian: Miks IONSYS heaks kiideti?
English: Therefore, the Committee decided that IONSYS's benefits are greater than its risks for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
Estonian: Komitee otsustas, et IONSYSi kasulikkus akuutse mõõduka kuni tugeva operatsioonijärgse valu vaigistamisel haiglatingimustes on suurem kui sellega kaasnevad riskid.
English: IONSYS is an iontophoretic transdermal system (ITS), which delivers the active substance, fentanyl hydrochloride, into the body through the skin.
Estonian: IONSYS on nahakaudse iontoforeesi seade, mis manustab toimeainet fentanüülhüdrokloriidi läbi naha.
English: Fentanyl, the active substance in IONSYS, can be abused.
Estonian: IONSYSi toimeainet fentanüüli on võimalik väärtarvitada.
English: The effects of IONSYS were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti INOSYSi toimet muude katsetega.
English: When the patient activates IONSYS, a small electrical current moves a dose of fentanyl from the reservoir through the skin and into the bloodstream.
Estonian: IONSYSi nupu vajutamisel liigub fentanüüli annus nõrga elektrivoolu toimel mahutist läbi naha vereringesse.
English: However, the risk with IONSYS is low, as the medicine is for short-term use.
Estonian: Et ravimit kasutatakse lühikest aega, on see risk IONSYSi kasutamisel väike.
English: IONSYS is used to control pain after an operation, in patients who are in hospital.
Estonian: IONSYSi kasutatakse operatsioonijärgse valu vaigistamiseks haiglapatsientidel.
English: The full EPAR for IONSYS can be found here.
Estonian: IONSYSi Euroopa avaliku hindamisaruande täisteksti leiate siit.
English: What is IONSYS used for?
Estonian: Milleks IONSYSi kasutatakse?
English: How is IONSYS used?
Estonian: Kuidas IONSYSi kasutatakse?
English: How does IONSYS work?
Estonian: Kuidas IONSYS toimib?
English: What benefit has IONSYS shown during the studies?
Estonian: Milles seisneb uuringute põhjal IONSYSi kasulikkus?
English: How has IONSYS been studied?
Estonian: Kuidas IONSYSi uuriti?
English: IONSYS contain the active ingredient fentanyl, which is a strong painkiller.
Estonian: IONSYSi toimeaine on tugev valuvaigisti fentanüül, mis on oopiumi derivaat.
English: 1 bottle + 1 syringe + 1 bottle adapter
Estonian: 1 pudel + 1 süstal + 1 pudeli adapter
English: Oral solution Oral use
Estonian: Suukaudne lahus
English: Date of first authorisation: 19 March 2002 Date of latest renewal: 21 February 2012
Estonian: Esmase müügiloa väljastamine: 19. märts 2002 Müügiloa uuendamine: 21. veebruar 2012
English: Do not squirt the medicine out quickly.
Estonian: Ärge pritsige ravimit kiiresti välja.
English: The following information is intended for medical or healthcare professionals only:
Estonian: Järgnev informatsioon on mõeldud ainult meditsiini- või tervishoiutöötajale:
English: Località Marino del Tronto 63100 Ascoli Piceno (AP) Italy
Estonian: Località Marino del Tronto 63100 Ascoli Piceno (AP) Itaalia
English: • Tablets must only be given if the child is able to swallow tablets.
Estonian: • Tablette tohib lapsele anda ainult juhul, kui laps on võimeline tablette neelama.
English: It has been shown that taking all doses at the appropriate times may greatly increase the effectiveness of your medicine.
Estonian: On näidatud, et kõigi annuste võtmine õigel ajal võib oluliselt suurendada ravimi efektiivsust.
English: Your treatment will be started as an infusion
Estonian: Teie ravi algab infusioonina
English: Other medicines and VFEND
Estonian: Muud ravimid ja VFEND
English: In this analysis a successful response was seen in 41% of patients in both treatment arms.
Estonian: Selles analüüsis esines edukas vastus 41% patsientidest mõlemas rühmas.
English: Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.
Estonian: Hetkel kättesaadavad andmed on kirjeldatud lõikudes 4.8 ja 5.1, aga annustamise soovitusi ei ole tehtud.
English: Keep it in a clean safe place with the medicine.
Estonian: Hoidke süstalt puhtas kindlas kohas koos ravimiga.
English: 1 bottle of 45 g
Estonian: 1 pudel 45 g
English: 6c Prime the IV line according to the manufacturer's guidelines.
Estonian: 6c Eeltäitke IV liin tootja juhtnööride kohaselt.
English: Do not stop treatment early because your infection may not be cured.
Estonian: Ärge lõpetage ravi liiga vara, sest infektsioon ei pruugi olla möödunud.
English: You should always add a total of 46 ml of water irrespective of the dose you are taking.
Estonian: Te peate alati lisama 46 ml vett sõltumata annusest, mida võtate.
English: • Cardiomyopathy, in particular when heart failure is present.
Estonian: • kardiomüopaatia, eriti südamepuudulikkuse korral
English: Further information is provided for medical or healthcare professionals at the end of the Package Leaflet.
Estonian: Edasine informatsioon meditsiini või tervishoiutöötajatele on saadaval pakendi infolehe lõpus.
English: However, some may be serious and need medical attention.
Estonian: Mõned kõrvaltoimed võivad siiski olla rasked ja vajada arstiabi.
English: Dry the two parts.
Estonian: 2 Kuivatage kahes osas.
English: If particles are seen, swirl again and re-inspect.
Estonian: Kui on näha osakesi, loksutage veel ja kontrollige uuesti.
English: Add 46 ml of water and shake vigorously for about 1 minute.
Estonian: Lisage 46 ml vett ja raputage energiliselt umbes 1 minut.
English: What VFEND is and what it is used for
Estonian: Mis ravim on VFEND ja milleks seda kasutatakse
English: Patients with a weakened immune system or those with difficult infections may require long-term treatment to prevent the infection from returning.
Estonian: Nõrgenenud immuunsüsteemiga või raskete infektsioonidega patsientidel võib osutuda vajalikuks pikaajaline ravi, et vältida infektsiooni taastumist.
English: This will force the medicine back into the bottle.
Estonian: See viib ravimi pudelisse tagasi.
English: 3c Swirl the vial gently until all the powder is dissolved.
Estonian: 3c Loksutage viaali kergelt, kuni kogu pulber on lahustunud.
English: The following instructions apply to both Treatment and Prophylaxis
Estonian: Järgnevad juhendid kehtivad mõlemale - ravile ja profülaktikale.
English: Clinical experience Successful outcome in this section is defined as complete or partial response.
Estonian: Kliiniline kogemus Käesolevas lõigus on kliiniline efektiivsus defineeritud kui täielik või osaline reageerimine ravile.
English: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline (ravimiohutuse või riski minimeerimise) eesmärk.
English: The adaptor is provided so that you can fill the oral syringe with medicine from the bottle.
Estonian: Adapter on lisatud selleks, et te saaksite täita süstla ravimiga otse pudelist.
English: Maximum increase in prothrombin time was approximately 2-fold.
Estonian: Protrombiiniaja maksimaalne pikenemine oli ligikaudu kahekordne
English: • you have had an allergic reaction to other azoles.
Estonian: • teil on esinenud allergilisi reaktsioone teiste asoolide suhtes;
English: Pull the plunger out of the syringe and wash both parts in warm soapy water.
Estonian: Tõmmake kolb välja ja peske mõlemad osad sooja seebiveega.
English: The asterisk (*) indicates a twoway interaction.
Estonian: Tärn (*) viitab mõlemasuunalisele koostoimele.
English: Includes akathisia and parkinsonism.
Estonian: Sealhulgas akatiisia ja parkinsonism.
English: Use in children and adolescents The recommended dose for children and teenagers is as follows:
Estonian: Kasutamine lastel ja noorukitel Soovitatav annus lastele ja noorukitele on järgmine:
English: Frequency categories are expressed as: Very common (1/10); Common (1/100 to 1/10); Uncommon (1/1,000 to 1/100); Rare (1/10,000 to 1/1,000); Very rare (1/10,000); Not known (cannot be estimated from the available data).
Estonian: Esinemissagedused on määratletud järgmiselt: väga sage (≥1/10), sage (≥1/100 kuni <1/10), aeg-ajalt (≥1/1000 kuni <1/100), harv (≥1/10 000 kuni <1/1000), väga harv (<1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Please see instructions below before using VFEND suspension.
Estonian: Palun lugege järgnevaid juhiseid, kui te kasutate VFEND suspensiooni.